Article · Health news

NICE updates four type 2 diabetes appraisals and withdraws four dapagliflozin appraisals

Health news Published · sources checked

NICE has updated four technology appraisals on type 2 diabetes medicines to match its type 2 diabetes guideline, and withdrawn four on dapagliflozin.

Key points

  • On 15 September 2026 NICE published a news story on updating four technology appraisals for type 2 diabetes.
  • The updated appraisals were brought into line with NICE's guideline on type 2 diabetes in adults.
  • NICE describes the exercise as the first test of a new way of keeping all of its guidance aligned.

What was announced

NICE has updated four technology appraisals for type 2 diabetes medicines so that they match the recommendations in its guideline on type 2 diabetes in adults. NICE says the pilot shows that appraisals can be kept aligned with guidelines more efficiently, without compromising the rigour or transparency of its decisions.

What it means

NICE also withdrew four appraisals on dapagliflozin: TA288, TA390, TA418 and TA583. It treats the withdrawal as a routing decision, and says it is not subject to appeal. NICE describes the exercise as the first test of a new way of keeping all of its guidance aligned.

More guides and news

Educational content. This article summarises public guidance and announcements in plain English for education. It is not medical advice and it cannot say what is right for you: speak to a clinician about your own health, call NHS 111 if you are unsure what to do and 999 in an emergency.